Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
JCXH-211 Combined With Anti-PD-1 Antibody in Malignant Solid Tumors
NCT06781125Phase 2Not yet recruiting
- Sponsor
- Immorna
- Start
- Mar 2026
- Primary completion
- Mar 2028
- Modality
- Lipid-based Nanoparticles, mRNA Therapeutics, Small Molecules
01
Overview
Phase 2, open-label, single-arm trial of JCXH-211 in malignant solid tumor, sponsored by Immorna. Primary endpoint: Dose-limiting toxicity at 28 days. Planned start Mar 2026; status: not yet recruiting.
02
Drugs
JCXH-211
03
Conditions
malignant solid tumor
Beyond the preview
Go deeper on NCT06781125.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06781125.